Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2936675rdf:typepubmed:Citationlld:pubmed
pubmed-article:2936675lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:2936675lifeskim:mentionsumls-concept:C0235490lld:lifeskim
pubmed-article:2936675lifeskim:mentionsumls-concept:C1555029lld:lifeskim
pubmed-article:2936675lifeskim:mentionsumls-concept:C0770949lld:lifeskim
pubmed-article:2936675pubmed:issue1lld:pubmed
pubmed-article:2936675pubmed:dateCreated1986-4-24lld:pubmed
pubmed-article:2936675pubmed:abstractTextAlthough there is no generally accepted therapy for ergotamine-induced vasoconstriction, infusion of directly acting vasodilators is regarded presently as the treatment of choice. We present a case of peripheral arterial ischaemia secondary to excessive use of ergotamine suppositories, which was reversed with oral thymoxamine hydrochloride (an alpha 1-adrenoceptor antagonist) and ergotamine withdrawal. We suggest that in patients with ergotamine-induced peripheral arterial vasoconstriction with no evidence of gangrene, oral thymoxamine may be considered as a useful adjunct or possible alternative to infused vasodilator treatment.lld:pubmed
pubmed-article:2936675pubmed:languageenglld:pubmed
pubmed-article:2936675pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2936675pubmed:citationSubsetIMlld:pubmed
pubmed-article:2936675pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2936675pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2936675pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2936675pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2936675pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2936675pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2936675pubmed:statusMEDLINElld:pubmed
pubmed-article:2936675pubmed:monthJanlld:pubmed
pubmed-article:2936675pubmed:issn0144-5952lld:pubmed
pubmed-article:2936675pubmed:authorpubmed-author:LevinM MMMlld:pubmed
pubmed-article:2936675pubmed:authorpubmed-author:JonesN SNSlld:pubmed
pubmed-article:2936675pubmed:issnTypePrintlld:pubmed
pubmed-article:2936675pubmed:volume5lld:pubmed
pubmed-article:2936675pubmed:ownerNLMlld:pubmed
pubmed-article:2936675pubmed:authorsCompleteYlld:pubmed
pubmed-article:2936675pubmed:pagination61-2lld:pubmed
pubmed-article:2936675pubmed:dateRevised2010-7-19lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:meshHeadingpubmed-meshheading:2936675-...lld:pubmed
pubmed-article:2936675pubmed:year1986lld:pubmed
pubmed-article:2936675pubmed:articleTitleErgotamine-induced peripheral ischaemia reversed by oral thymoxamine hydrochloride.lld:pubmed
pubmed-article:2936675pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2936675pubmed:publicationTypeCase Reportslld:pubmed